Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

A WuXi PharmaTech CMO Facility Attains US GMP Certification

publication date: Oct 30, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
WuXi PharmaTech said one of its contract manufacturing facilities passed a US FDA inspection. The facility, a small molecule API and advanced intermediate manufacturing plant, is owned by a WuXi subsidiary, Shanghai SynTheAll Pharma (STA). The US FDA completed a general GMP and Pre-Approval Inspection of the facility without issuing a Form 483. More details....

Stock Symbol: (NYSE: WX)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...